Organon & Co. (NYSE:OGN) Sets New 52-Week High – Time to Buy?

Organon & Co. (NYSE:OGN) reached a new 52-week high during trading on Monday . The stock traded as high as $13.77 and last traded at $13.7650, with a volume of 1003 shares traded. The stock had previously closed at $13.76.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, August 3rd. Five equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus price target of $11.40.

Organon & Co. Stock Performance

The business’s fifty day moving average is $13.58 and its two-hundred day moving average is $11.12. The company has a quick ratio of 1.44, a current ratio of 1.95 and a debt-to-equity ratio of 8.43. The stock has a market capitalization of $3.61 billion, a PE ratio of 17.88, a price-to-earnings-growth ratio of 1.27 and a beta of 1.55.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $0.02 dividend. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Organon & Co.’s dividend payout ratio (DPR) is presently 10.39%.

Institutional Trading of Organon & Co.

A number of large investors have recently made changes to their positions in OGN. Royal Bank of Canada raised its holdings in Organon & Co. by 53.4% during the 1st quarter. Royal Bank of Canada now owns 360,862 shares of the company’s stock valued at $5,374,000 after buying an additional 125,648 shares during the period. Goldman Sachs Group Inc. lifted its stake in Organon & Co. by 126.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company’s stock worth $21,370,000 after purchasing an additional 801,307 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Organon & Co. by 2.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,042,991 shares of the company’s stock valued at $15,530,000 after buying an additional 26,640 shares during the period. Focus Partners Wealth boosted its position in shares of Organon & Co. by 33.2% during the first quarter. Focus Partners Wealth now owns 55,875 shares of the company’s stock valued at $832,000 after buying an additional 13,925 shares during the period. Finally, XTX Topco Ltd bought a new position in shares of Organon & Co. during the second quarter valued at approximately $107,000. 77.43% of the stock is currently owned by institutional investors.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.